HORIBA Medical, the clinical diagnostic industry’s trusted partner, today announced the CE IVDR registration of three new Yumizen C clinical chemistry analyzers offering new levels of instrument and reagent synergy.
Paired with the company’s comprehensive, high-quality POINTE reagents package, the new Yumizen C analyzers will provide quick and reliable results, featuring robust hardware and advanced software – all backed by HORIBA Medical’s gold-standard service and support organization.
“These new analyzers demonstrate our commitment to serving patients relying on rapid, reliable diagnoses and monitoring, by delivering consistent, accurate results,” said Riad Abuelafiya, vice president and general manager at HORIBA Medical. “Mid-sized and small labs can depend on our new Yumizen brand devices for cost-efficient, reliable diagnostics.”
For mid-sized labs in the U.S. and globally, HORIBA Medical announces CE IVDR registration and US FDA clearance for the workhorse Yumizen C560 analyzer, a stand-alone floor model offering high-end features typically found only in large, integrated systems.
In addition, outside of the US, HORIBA Medical has obtained CE IVDR registration for the Yumizen C240 and Yumizen C230 analyzers. The Yumizen C240 is a compact and cost-efficient offering, with full walk-away capabilities and advanced features for mid-sized to small labs. The Yumizen C230 is designed for smaller laboratories, with advanced, user-friendly features.
The new Yumizen C clinical analyzers have debuted at the Medlab Middle East 2023 conference, Feb. 6 to 9, at the Dubai World Trade Center, UAE. Visit HORIBA Medical at booth #Z4.E10.
